The contribution of paternal chromatin to chromosome segregation errors in human pre-implantation embryos.

The contribution of paternal chromatin to chromosome segregation errors in human pre-implantation embryos. - Impact of paternal chromatin on embryo aneuploidy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35343

Enrollment

621

Registered

2012-03-13

Start date

2012-04-25

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryo quality sperm quality

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Written informed consent

Exclusion criteria

Exclusion criteria: No surplus embryos available Surplus embryos with excessive degeneration or fragmentation (>50%)

Design outcomes

Primary

Measure	Time frame
In the first part of the study, human tripronuclear zygotes and surplus embryos will be arrested at prometaphase by colcemid treatment, to visualize chromosomes and study protein markers by immunofluorescence. In addition mRNA expression of relevant genes will be assessed. The second part uses an established assay that generates a high frequency of chromosome attachment errors by treatment with monastrol, followed by monastrol withdrawal and monitoring of the correction of these attachment errors. For part I, the primary study parameter is presence and localization of a set of marker proteins, informative for heterochromatin formation and associated proteins on the pericentric region from paternal versus maternal chromosomes in embryos at different stages of development. For part II, the primary outcome measure is the frequency of alignment failure of paternal versus maternal chromosomes.	—

Measure

Time frame

In the first part of the study, human tripronuclear zygotes and surplus embryos will be arrested at prometaphase by colcemid treatment, to visualize chromosomes and study protein markers by immunofluorescence. In addition mRNA expression of relevant genes will be assessed. The second part uses an established assay that generates a high frequency of chromosome attachment errors by treatment with monastrol, followed by monastrol withdrawal and monitoring of the correction of these attachment errors. For part I, the primary study parameter is presence and localization of a set of marker proteins, informative for heterochromatin formation and associated proteins on the pericentric region from paternal versus maternal chromosomes in embryos at different stages of development. For part II, the primary outcome measure is the frequency of alignment failure of paternal versus maternal chromosomes.

—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results